| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy
|
Scott, Hamish S
|
|
|
142 |
S2 |
p. LBA-6
|
artikel
|
| 2 |
Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
|
Wang, Michael
|
|
|
142 |
S2 |
p. LBA-2
|
artikel
|
| 3 |
PATH-HHT, a Double-Blind, Randomized, Placebo-Controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life
|
Al-Samkari, Hanny
|
|
|
142 |
S2 |
p. LBA-3
|
artikel
|
| 4 |
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
|
Sonneveld, Pieter
|
|
|
142 |
S2 |
p. LBA-1
|
artikel
|
| 5 |
Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507
|
Kassim, Adetola A.
|
|
|
142 |
S2 |
p. LBA-4
|
artikel
|
| 6 |
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
|
Aldoss, Ibrahim
|
|
|
142 |
S2 |
p. LBA-5
|
artikel
|
Tijdschrift beschrijving